femasys logo 2.jpg
Femasys to Participate in Fireside Chat to Discuss the Infertility Treatment Landscape on March 21, 2024
March 13, 2024 09:00 ET | Femasys Inc.
-- CEO Kathy Lee-Sepsick and Chief Medical Officer James Liu to Join Jones Trading Analyst Catherine Novack in a Conversation on Current Treatment Options in Infertility Including FemaSeed® at 1PM ET...
BEAM-Logo-Color and Black-Large-576x375.png
Beam Global Announces New Federal Customers Placed First-Time Orders for EV ARC Solar-Powered EV Charging Systems
February 13, 2024 06:00 ET | Beam Global
Beam Global Announces New Federal Customers Placed First-Time Orders for EV ARC Solar-Powered EV Charging Systems
BioCardia-Final-Logo-2016-JPEG.jpg
BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA
February 08, 2024 07:00 ET | BioCardia, Inc.
SUNNYVALE, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (“BioCardia” or the “Company”) (Nasdaq: BCDA), a biotechnology company focused on advancing late-stage cell therapy interventions...
Robbins LLP logo white Background.png
Robbins LLP Reminds Brainstorm Cell Therapeutics Inc. Investors of Upcoming Lead Plaintiff Deadline in Class Action Against BCLI
December 15, 2023 17:36 ET | Robbins LLP
Brainstorm Cell Therapeutics Inc. (BCLI) Misled Investors About the Viability and Efficacy of its drug NurOwn
NTTSNew
New to The Street Announces Five Corporate Interviews, Episode 535, Airing on the FOX Business Network on Monday, December 4, 2023, at 10:30 PM PT
December 01, 2023 09:30 ET | FMW Media Works Corp
New to The Street Announces Five Corporate Interviews, Episode 535, Airing on the FOX Business Network on Monday, December 4, 2023, at 10:30 PM PT
BioCardia-Final-Logo-2016-JPEG.jpg
BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure
November 14, 2023 07:15 ET | BioCardia, Inc.
SUNNYVALE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
Robbins LLP logo white Background.png
KVUE Class Action Notice: Robbins LLP Reminds Informs Investors of Lead Plaintiff Deadline in Kenvue Inc. Securities Fraud Class Action
October 16, 2023 14:08 ET | Robbins LLP
Kenvue Inc. (KVUE) Made False and Misleading Statements in its Registration Statement in Support of its IPO
Robbins LLP logo white Background.png
Integra Lifesciences Holdings Corporation (IART) Investor Alert: Robbins LLP Reminds Investors of Class Action Filed Against Integra Lifesciences Holdings Corporation
September 18, 2023 12:14 ET | Robbins LLP
SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons or entities that purchased or otherwise acquired Integra...
Robbins LLP logo white Background.png
IBRX Stock News: Contact Robbins LLP for Information Regarding ImmunityBio, Inc. Class Action
July 18, 2023 18:31 ET | Robbins LLP
SAN DIEGO, July 18, 2023 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired...
EDVO
New to The Street TV Signs 6 Part Series, Featuring Endonovo Therapeutics, Inc.
June 22, 2023 13:02 ET | FMW Media Works Corp
NEW YORK, June 22, 2023 (GLOBE NEWSWIRE) -- FMW Media Works' New to The Street will feature Endonovo Therapeutics, Inc. (OTCQB: ENDV) ($ENDV) on its nationally syndicated and sponsored television...